Malignant Tumor Of Head And Or Neck — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for malignant tumor of head and or neck. 18 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
18
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Malignant Tumor Of Head And Or Neck

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sanofi 18 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating malignant tumor of head and or neck. Each bar = one year. Y-axis scaled to peak year (9 patents).

3
31
9
33
6
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Taxotere
Docetaxel
 Sanofi 18 59 — 2031-08-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11419842 Taxotere method of use 75 2036-05-16
12090134 Taxotere method of use 75 2036-05-16
10842770 Taxotere method of use 68 2031-08-07
10842770 Taxotere method of use 68 2031-08-07
10842770 Taxotere method of use 68 2031-08-07
9763880 Taxotere method of use 62 2033-09-30
9763880 Taxotere method of use 62 2033-09-30
9763880 Taxotere method of use 62 2033-09-30
8940786 Taxotere method of use 62 2033-09-30
8940786 Taxotere method of use 62 2033-09-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9308195 Taxotere formulation 42 2033-09-30
9308195 Taxotere formulation 42 2033-09-30
9308195 Taxotere formulation 42 2033-09-30
10398785 Taxotere formulation 50 2036-03-14
10398785 Taxotere formulation 50 2036-03-14
10398785 Taxotere formulation 50 2036-03-14
12090135 Taxotere formulation 55 2036-05-16
9763880 Taxotere method of use 62 2033-09-30
8940786 Taxotere method of use 62 2033-09-30
8940786 Taxotere method of use 62 2033-09-30

Related